193 related articles for article (PubMed ID: 35441522)
1. Real-world treatment patterns and overall survival in
Atkins MB; Julian C; Secrest MH; Lee J; Abajo-Guijarro AM; McKenna E
Future Oncol; 2022 Jun; 18(18):2233-2245. PubMed ID: 35441522
[TBL] [Abstract][Full Text] [Related]
2. Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma.
Kartolo A; Deluce J; Hopman WM; Liu L; Baetz T; Ernst S; Lenehan JG
Curr Oncol; 2022 Mar; 29(3):1501-1513. PubMed ID: 35323326
[TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.
Betof Warner A; Tarhini A; Kang B; Nakasato A; Ling YL; Shah R; Tang J; Patel J
Melanoma Res; 2023 Feb; 33(1):38-49. PubMed ID: 36545921
[TBL] [Abstract][Full Text] [Related]
4. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
[TBL] [Abstract][Full Text] [Related]
5. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
6. Treatment management for
Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
[TBL] [Abstract][Full Text] [Related]
7. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
[TBL] [Abstract][Full Text] [Related]
8. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
Wang X; Haaland B; Hu-Lieskovan S; Colman H; Holmen SL
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1419. PubMed ID: 34137219
[TBL] [Abstract][Full Text] [Related]
9. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
[No Abstract] [Full Text] [Related]
10. The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study.
Haist M; Stege H; Ebner R; Fleischer MI; Loquai C; Grabbe S
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565212
[TBL] [Abstract][Full Text] [Related]
11. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
12. First-line immunotherapy versus targeted therapy in patients with
Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
[No Abstract] [Full Text] [Related]
13. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
14. Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.
Ferrucci PF; Lens M; Cocorocchio E
Curr Oncol Rep; 2021 Nov; 23(12):138. PubMed ID: 34735635
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
16. Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.
Ziogas DC; Konstantinou F; Bouros S; Gogas H
Expert Rev Anticancer Ther; 2020 Jan; 20(1):53-62. PubMed ID: 31903803
[No Abstract] [Full Text] [Related]
17. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France.
Sassolas B; Leccia MT; Godard C; Benmahamed L; Flinois A; Levy-Bachelot L; Bédane C
J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):587-594. PubMed ID: 28960564
[TBL] [Abstract][Full Text] [Related]
19. Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice.
Mangana J; Zihler D; Bossart S; Brönnimann D; Zachariah R; Gérard CL
Melanoma Res; 2022 Oct; 32(5):366-372. PubMed ID: 35855650
[TBL] [Abstract][Full Text] [Related]
20. Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.
Trojaniello C; Sparano F; Cioli E; Ascierto PA
Curr Oncol Rep; 2023 Jun; 25(6):623-634. PubMed ID: 36995534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]